LIGHTBRIDGE Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LIGHTBRIDGE Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 25, 2021 |
| FY2018 | Dec 31, 2017 | $175.4K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $760.6K | Mar 14, 2018 |
| FY2016 | Dec 31, 2015 | $910.5K | Mar 23, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2017 | $68.4K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $304.0K | Mar 14, 2018 |
| FY2016 | Dec 31, 2015 | $216.2K | Mar 23, 2017 |
| FY2015 | Dec 31, 2014 | $553.9K | Mar 15, 2016 |
| FY2014 | Dec 31, 2013 | $791.5K | Nov 23, 2015 |
| FY2013 | Dec 31, 2012 | $1.41M | Mar 27, 2014 |
| FY2012 | Dec 31, 2011 | $2.36M | Mar 1, 2013 |
| FY2011 | Dec 31, 2010 | $2.65M | Feb 22, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.58M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($11.79M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($7.91M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($7.50M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($7.84M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($14.42M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($10.68M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($15.68M) | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | ($7.10M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($6.35M) | Mar 14, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.23M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($13.06M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($9.04M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($7.79M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($7.88M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($14.50M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($11.07M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($14.95M) | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | ($6.60M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($7.63M) | Mar 14, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.21M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.60M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.92M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $669.8K | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $1.37M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $891.6K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.68M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $3.46M | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | $2.28M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $2.75M | Mar 14, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.28M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($9.49M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($6.48M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($6.76M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($11.04M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($8.57M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($6.67M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($7.42M) | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | ($5.00M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($5.98M) | Mar 14, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $203.83M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $40.95M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $29.40M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $29.47M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $24.96M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $21.79M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $19.55M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $26.34M | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | $6.95M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $6.80M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.15M | Mar 14, 2018 |
| FY2017 | Dec 31, 2016 | $1.24M | Mar 14, 2018 |
| FY2016 | Dec 31, 2015 | $3.71M | Mar 23, 2017 |
| FY2015 | Dec 31, 2014 | $5.29M | Mar 15, 2016 |
| FY2014 | Dec 31, 2013 | $2.19M | Nov 23, 2015 |
| FY2013 | Dec 31, 2012 | $385.2K | Mar 27, 2014 |
| FY2012 | Dec 31, 2011 | $1.68M | Mar 1, 2013 |
| FY2011 | Dec 31, 2010 | $2.19M | Feb 22, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $202.99M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $40.53M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $28.91M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $29.12M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $24.79M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | $17.21M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $19.20M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $25.30M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $5.79M | Mar 18, 2020 |
| FY2018 | Dec 31, 2016 | $5.56M | Mar 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($183.77M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($164.18M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($152.40M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($144.49M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($136.99M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($129.16M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($114.74M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($103.50M) | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | ($87.82M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($80.72M) | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $28.90M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $24.75M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $21.53M | Mar 31, 2022 |
| FY2019 | Mar 18, 2020 | $16.50M | Mar 18, 2020 |
| FY2021 | Dec 31, 2019 | $17.96M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $24.64M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $4.52M | Mar 18, 2020 |
| FY2018 | Dec 31, 2016 | $3.58M | Mar 29, 2019 |
| FY2017 | Dec 31, 2015 | $623.2K | Mar 14, 2018 |
| FY2016 | Dec 31, 2014 | $4.22M | Mar 23, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0 | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | (1) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | (3) | Mar 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 3, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 3, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | (1) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | (3) | Mar 25, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 33.41M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 18.78M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 13.70M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 11.90M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | 9.76M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 6.57M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 3.25M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 2.74M | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | 12.74M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 7.11M | Mar 14, 2018 |